HCPCS Level II code J7211 denotes the injectable recombinant factor VIII product Kovaltry, billed per 1 international unit. This code is central to billing for replacement therapy in hemophilia A and matters nationally due to the high cost, specialized supply chain, and frequent infusion-based care required for affected patients. Payers commonly involved in coverage and reimbursement for this code include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will learn what J7211 represents clinically and operationally, where the service is typically delivered, and key considerations for billing and payment. The publication provides benchmarks and context for reimbursement, notes common modifiers and payer practices, and summarizes clinical use of recombinant factor VIII products. It also highlights policy-relevant issues such as site-of-care implications and the role of specialty pharmacy and infusion services in managing high-cost biologic therapies.

Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes is noted where applicable elsewhere in the full publication.